Docosahexaenoic acid-mediated protein aggregates may reduce proteasome activity and delay myotube degradation during muscle atrophy in vitro

다국어 초록 (Multilingual Abstract)

Proteasomes are the primary degradation machinery for oxidatively damaged proteins that compose a class of misfolded protein substrates. Cellular levels of reactive oxygen species increase with age and this cellular propensity is particularly harmful when combined with the age-associated development of various human disorders including cancer, neurodegenerative disease and muscle atrophy. Proteasome activity is reportedly downregulated in these disease conditions. Herein, we report that docosahexaenoic acid (DHA), a major dietary omega-3 polyunsaturated fatty acid, mediates intermolecular protein cross-linkages through oxidation, and the resulting protein aggregates potently reduce proteasomal activity both in vitro and in cultured cells. Cellular models overexpressing aggregation-prone proteins such as tau showed significantly elevated levels of tau aggregates and total ubiquitin conjugates in the presence of DHA, thereby reflecting suppressed proteasome activity. Strong synergetic cytotoxicity was observed when the cells overexpressing tau were simultaneously treated with DHA. Antioxidant N-acetyl cysteine significantly desensitized the cells to DHA-induced oxidative stress. DHA significantly delayed the proteasomal degradation of muscle proteins in a cellular atrophy model. Thus, the results of our study identified DHA as a potent inducer of cellular protein aggregates that inhibit proteasome activity and potentially delay systemic muscle protein degradation in certain pathologic conditions.

참고문헌 (Reference)

1 McGreal RS, "alphaB-crystallin/sHSP protects cytochrome c and mitochondrial function against oxidative stress in lens and retinal cells" 1820 : 921-930, 2012

2 Jagoe RT, "What do we really know about the ubiquitinproteasome pathway in muscle atrophy?" 4 : 183-190, 2001

3 Sala-Vila A, "Update on the relationship of fish intake with prostate, breast, and colorectal cancers" 51 : 855-871, 2011

4 Finley D, "Ubiquitin as a central cellular regulator" 116 : S29-S32, 2004

5 Tisdale MJ, "The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting" 3 : 209-217, 2005

6 Zhang X, "The proteasome : a target of oxidative damage in cultured human retina pigment epithelial cells" 49 : 3622-3630, 2008

7 Wigmore SJ, "The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer" 12 : S27-S30, 1996

8 Mandelkow EM, "Tau in Alzheimer’s disease" 8 : 425-427, 1998

9 Lee MJ, "Tau degradation: the ubiquitinproteasome system versus the autophagy-lysosome system" 105 : 49-59, 2013

10 Bandyopadhyay B, "Tau aggregation and toxicity in a cell culture model of tauopathy" 282 : 16454-16464, 2007

11 Finley D, "Recognition and processing of ubiquitin-protein conjugates by the proteasome" 78 : 477-513, 2009

12 Solomon V, "Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway" 95 : 12602-12607, 1998

13 Hough R, "Purification of two high molecular weight proteases from rabbit reticulocyte lysate" 262 : 8303-8313, 1987

14 Pariat M, "Proteolysis by calpains: a possible contribution to degradation of p53" 17 : 2806-2815, 1997

15 Stadtman ER, "Protein oxidation and aging" 40 : 1250-1258, 2006

16 Moreau KL, "Protein misfolding and aggregation in cataract disease and prospects for prevention" 18 : 273-282, 2012

17 Goldberg AL, "Protein degradation and protection against misfolded or damaged proteins" 426 : 895-899, 2003

18 Baugh JM, "Proteasomes can degrade a significant proportion of cellular proteins independent of ubiquitination" 386 : 814-827, 2009

19 Pickart CM, "Proteasomes and their kin: proteases in the machine age" 5 : 177-187, 2004

20 Cornwell DG, "Polyunsaturated fatty acids, vitamin E, and the proliferation of aortic smooth muscle cells" 14 : 194-207, 1979

21 Ding WQ, "Phospholipid hydroperoxide glutathione peroxidase plays a role in protecting cancer cells from docosahexaenoic acid-induced cytotoxicity" 6 : 1467-1474, 2007

22 Burns CP, "Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia : cancer and leukemia group B study 9473" 5 : 3942-3947, 1999

23 Lee JH, "Pharmacological Modulation of the N-End Rule Pathway and its Therapeutic Implications" 36 : 782-797, 2015

24 Sies H, "Oxidative stress: oxidants and antioxidants" 82 : 291-295, 1997

25 Sies H., "Oxidative stress: from basic research to clinical application" 91 : 31S-38S, 1991

26 Zhu X, "Oxidative stress signalling in Alzheimer’s disease" 1000 : 32-39, 2004

27 Choi WH, "Nat Commun" 7 : 10963-, 2016

28 Lecker SH, "Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression" 18 : 39-51, 2004

29 Wojcik C, "Modulation of adipocyte differentiation by omega-3 polyunsaturated fatty acids involves the ubiquitin-proteasome system" 18 : 590-599, 2014

30 Powers SK, "Mechanisms of disuse muscle atrophy: role of oxidative stress" 288 : R337-R344, 2005

31 Tisdale MJ, "Mechanisms of cancer cachexia" 89 : 381-410, 2009

32 Vaughan VC, "Marine polyunsaturated fatty acids and cancer therapy" 108 : 486-492, 2013

33 Tisdale MJ, "Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia" 12 : S31-S33, 1996

34 Kisselev AF, "Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate" 281 : 8582-8590, 2006

35 Huttner JJ, "Fatty acids and their prostaglandin derivatives: inhibitors of proliferation in aortic smooth muscle cells" 197 : 289-291, 1977

36 Lee JH, "Facilitated Tau Degradation by USP14 Aptamers via Enhanced Proteasome Activity" 5 : 10757-, 2015

37 Lee BH, "Enhancement of proteasome activity by a small-molecule inhibitor of USP14" 467 : 179-184, 2010

38 MacLean CH, "Effects of omega-3 fatty acids on cancer risk: a systematic review" 295 : 403-415, 2006

39 Wigmore SJ, "Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer" 36 : 177-184, 2000

40 Jing K, "Docosahexaenoic acid induces autophagy through p53/AMPK/mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53" 7 : 1348-1358, 2011

41 Han DH, "Direct cellular delivery of human proteasomes to delay tau aggregation" 5 : 5633-, 2014

42 Son YH, "Dexamethasone downregulates caveolin-1 causing muscle atrophy via inhibited insulin signaling" 225 : 27-37, 2015

43 Jiang Y, "Characterization of mammalian N-degrons and development of heterovalent inhibitors of the N-end rule pathway" 4 : 3339-3346, 2013

44 Taggart CC, "Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor" 276 : 33345-33352, 2001

45 Cuervo AM, "Autophagy and aging: the importance of maintaining ‘clean’ cells" 1 : 131-140, 2005

46 Sahara N, "Assembly of two distinct dimers and higher-order oligomers from full-length tau" 25 : 3020-3029, 2007

47 Jiang Y, "A neurostimulant para-chloroamphetamine inhibits the arginylation branch of the N-end rule pathway" 4 : 6344-, 2014